

(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 541 147 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
15.06.2005 Bulletin 2005/24

(51) Int Cl.7: A61K 31/4458, A61K 9/50

(21) Application number: 05075103.1

(22) Date of filing: 09.06.1998

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE

(30) Priority: 14.07.1997 US 892190

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
98926529.3 / 1 001 772

(71) Applicants:

- MEHTA, Atul M.
Ramsey, NJ 07446 (US)
- Zeitlin, Andrew L.
Millington, NJ 07946 (US)
- Dariani, Maghsoud M.
Fanwood, NJ 07023 (US)

(72) Inventors:

- Zeitlin, Andrew L.
Millington, NJ 07946 (US)
- Dariani, Maghsoud M.
Fanwood, NJ 07023 (US)

(74) Representative: Hallybone, Huw George et al
Carpmaels and Ransford,
43-45 Bloomsbury Square
London WC1A 2RA (GB)

Remarks:

This application was filed on 14-01-2005 as a
divisional application to the application mentioned
under INID code 62.

(54) Improved delivery of multiple doses of a methylphenidate drug

(57) Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release profile, the dosage forms eliminate the need for a

patient to carry and additional dose for ingestion during the day. The dosage forms and methods provided are useful in administering methylphenidate and pharmaceutically acceptable salts thereof, which generally require one or more doses throughout the day.

Description

FIELD OF THE INVENTION

5 [0001] The present invention relates to improved dosing of medications. In particular, the present invention relates to improved dosing of a medication whereby two or more effective, time-separated doses may be provided by administration of a single dosage unit. The second, and any later, dose is time-delayed following administration. Based on predictable *in vitro* release times, the dosage forms can be formulated to deliver delayed doses *in vivo* at desired times.





10 [0002] The dosage forms and methods of the present invention are particularly suitable for the administration of methylphenidate hydrochloride, and especially for the administration of a single isomer, *d*-*threo*-methylphenidate hydrochloride.

15 [0003] The administration of dosage forms which contain an immediate dosage and a delayed second dosage provides for reduced abuse potential, improved convenience of administration, and better patient compliance, especially when methylphenidate is used to treat certain central nervous system disorders.

BACKGROUND OF THE INVENTION

20 [0004] Attention Deficit Disorder (ADD), a commonly diagnosed nervous system illness in children, is generally treated with methylphenidate hydrochloride (available commercially as, e.g., Ritalin®). Symptoms of ADD include distractibility and impulsivity. A related disorder, termed Attention Deficit Hyperactivity Disorder (ADHD), is further characterized by symptoms of hyperactivity, and is also treated with methylphenidate hydrochloride. Methylphenidate drugs have also been used to treat cognitive decline in patients with Acquired Immunodeficiency Syndrome (AIDS) or AIDS related conditions. See, e.g., Brown, G., *Intl. J. Psych. Med.* 25(1): 21-37 (1995); Holmes et al., *J. Clin. Psychiatry* 50: 5-8 (1989).

25 [0005] Methylphenidate exists as four separate optical isomers as follows:

35 *L-threo**d-erythro*45 *d-threo**L-erythro*

50 wherein R₂ is phenyl. Pharmaceutically acceptable salts are generally administered clinically. Other phenidate drugs, which also can be administered according to the invention, include those in which the methyl group in the above structures is replaced by C₂-C₄ alkyl and R₂ is optionally substituted with C₁-C₄ alkyl.

55 [0006] Clinically, the *threo* pair of enantiomers of methylphenidate hydrochloride is generally administered for the treatment of ADD and ADHD. The hydrochloride salt is commonly referred to simply as "methylphenidate". Unless indicated otherwise, the term "methylphenidate" is used broadly herein to include methylphenidate and pharmaceuti-

cally acceptable salts thereof, including methylphenidate hydrochloride.

[0007] The *threo* racemate (pair of enantiomers) of methylphenidate is a mild central nervous system stimulant with pharmacological activity qualitatively similar to that of amphetamines. Undesirable side effects associated with the use of the *dl-threo* racemate of methylphenidate include anorexia, weight loss, insomnia, dizziness and dysphoria. Furthermore, the racemate, which is a Schedule II controlled substance, produces a euphoric effect when administered intravenously or through inhalation or ingestion, and thus carries a high potential for abuse.

[0008] Srinivas et al. studied the administration of *dl-threo*-, *d-threo*-, and *l-threo*-methylphenidate to children suffering from ADHD, and reported that the pharmacodynamic activity of *dl-threo*-methylphenidate resides in the *d-threo* isomer (*Clin. Pharmacol. Ther.*, 52: 561-568 (1992)). Therefore, while *dl-threo*-methylphenidate is generally used therapeutically, this racemate includes the *l* isomer which apparently makes no significant contribution to the pharmacological effectiveness of the drug, but likely contributes to the associated side effects. It is thus desirable to administer only the active *d-threo* form of the drug.

[0009] An additional problem is that children being treated with *dl-threo* methylphenidate must generally take one or more doses during the day. This creates a problem for school administrators who must store a controlled substance on school premises, with the associated risk that it may be stolen for illicit use. Furthermore, children may be traumatized by ridicule from peers when they must take medication at school.

[0010] Sustained release formulations of *dl-threo* methylphenidate have been developed, which provide for slow release of the drug over the course of the day. However, it has been observed that peak plasma concentrations of the drug are lower when sustained release formulations are used. In some studies, sustained release formulations of methylphenidate have been shown to have lower efficacy than conventional dosage forms.

[0011] There remains a need for methods for delivering methylphenidate with maximum effectiveness and minimal potential for abuse. Furthermore, it has been determined that there is a need for a dosage form which provides, in one administration, an initial release followed, at a predictable delay, by a second release, of maximally effective methylphenidate. This will eliminate the risk of theft or loss of the second dose, while minimizing undesirable side effects and maximizing ease of administration. The present invention is directed to these, as well as other, important ends.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012]

Figure 1 depicts an *in vitro* time-concentration relationship (release profile) for certain preferred dosage forms in accordance with the invention.

Figure 2 depicts a schematic representation of *in vivo* plasma concentration of a drug released according to the release profile shown in Figure 1.

SUMMARY OF THE INVENTION

[0013] The present invention provides, in one embodiment, a therapeutic composition for the oral administration of a methylphenidate drug comprising a dosage form containing two groups of particles, each containing the methylphenidate drug. The term "particles", as used herein, includes pellets, granules, and the like. The first group of particles provides a substantially immediate dose of the methylphenidate drug upon ingestion by a mammal. The first group of particles can also comprise a coating and/or sealant. The second group of particles comprises coated particles, which comprise from about 2% to about 75%, preferably from about 2.5% to about 50%, and more preferably from about 5% to about 20%, by weight of the second group of particles, of the methylphenidate drug, in admixture with one or more binders. The coating comprises a pharmaceutically acceptable ammonio methacrylate copolymer in an amount sufficient to provide a delay of from about 2 hours to about 7 hours following ingestion before release of the second dose. If desired, one or more additional doses may be delivered by additional particles, coated in a similar manner, but with a sufficient amount of ammonio methacrylate copolymer coating to provide the dosage after an additional delay. Methylphenidate and pharmaceutically acceptable salts thereof, including methylphenidate hydrochloride, can be prepared into the dosage forms of the invention.

[0014] In one embodiment of the present invention, the first group of particles comprises a methylphenidate drug and provides a substantially immediate dose of the methylphenidate drug upon ingestion by a mammal. The first group of particles may comprise a coating and/or sealant. The second group of particles comprises coated particles, which comprise from about 2% to about 75%, preferably from about 2.5% to about 50%, and more preferably from about 5% to about 20%, by weight of the particles of the methylphenidate drug in admixture with one or more binders. The coating comprises a pharmaceutically acceptable ammonio methacrylate copolymer in a quantity sufficient to provide a dose of methylphenidate delayed by from about 2 hours to about 7 hours following ingestion.

[0015] For example, the first group of particles can comprise a pharmaceutically acceptable salt of methylphenidate,

such as methylphenidate hydrochloride, in powder form, or coated or uncoated particles containing the methylphenidate salt. The amount of methylphenidate salt in each group of particles can vary, depending upon the dosage requirements of the patient to whom the drug is to be administered. Generally, the daily dosage requirement for methylphenidate drugs is from about 1 mg to about 50 mg per day, preferably from about 2 mg to about 20 mg, and more preferably from about 2.5 to about 12 mg per day. The actual dosage to be administered will be determined by the attending physician as a matter of routine. Thus, depending upon the amounts of coating and/or and optional excipients and other additives, the amount of methylphenidate drug can be, for example, from about 2% to about 99% by weight of the first group of particles. In addition to the methylphenidate drug, the second group of particles comprises a filler, such as a hydrophobic filler, one or more ammonio methacrylate copolymers, and optional excipients and other additives. The filler can be present in an amount of, for example, from about 35% to about 45%, by weight, based on the total weight of the second group of particles.

[0016] Another embodiment of the present invention provides a method for treating disease, such as, for example, ADD, ADHD, or AIDS-related dementia, in a patient in need of treatment. This treatment comprises administering to the patient a dosage form providing once-daily oral administration of a methylphenidate drug such as methylphenidate hydrochloride. The dosage form comprises at least two groups of particles, each containing the methylphenidate drug. The first group of particles comprises from about 2% to about 99% by weight of the methylphenidate drug, depending upon desired the daily dosage, and provides a substantially immediate dose of methylphenidate upon ingestion by a mammal. The first group may comprise a coating and/or sealant. The second group of particles comprises coated particles. The coated particles comprise the methylphenidate drug in admixture with one or more binders, wherein the amount of methylphenidate drug is from about 2% to about 75%, preferably from about 2.5 % to about 50%, and more preferably from about 5% to about 20 %, by weight of the second group of particles, and a coating comprising an ammonio methacrylate copolymer in a quantity sufficient to provide a dose of methylphenidate delayed by from about 2 hours to about 7 hours following ingestion. The components of the two groups of particles can vary as described hereinabove. The initial dose can be administered separately from the delayed dose, if desired.

[0017] A further embodiment of the present invention provides dosage forms for the oral administration, in a single dosage form, of two doses of a pharmaceutically acceptable salt of *d*-*threo*-methylphenidate. The dosage forms comprise particles containing within their interiors from about 2% to about 75%, preferably from about 2.5% to about 50%, and more preferably from about 5% to about 20 %, of the *d*-*threo*-methylphenidate salt, in admixture with one or more binders. The particles have a coating exterior to the methylphenidate salt, which comprises an ammonio methacrylate copolymer in a quantity sufficient to delay release of the *d*-*threo*-methylphenidate salt contained within by from about 2 hours to about 7 hours following administration. The dosage forms also comprise, exterior to the coating, an outer layer comprising from about 2% to about 99% by weight of the *d*-*threo*-methylphenidate salt, based on the weight of all components in the outer layer, to provide a substantially immediate dose of the *d*-*threo*-methylphenidate salt upon administration. The layer comprising the immediate dose of the *d*-*threo*-methylphenidate salt can, if desired, further comprise an outer sealant layer. If desired, the two doses of the *d*-*threo*-methylphenidate salt can be approximately equal.

[0018] The present invention also provides dosage forms providing plasma concentration profiles for methylphenidate having two maxima, temporally separated from each other by from about 2 hours to about 7 hours. Preferably, the magnitude of said maxima differs by no more than about 30 percent, more preferably by no more than about 20 percent, and most preferably by no more than about 10 percent.

[0019] "Methylphenidate" as used herein, includes all four optical isomers of the compound and all pharmaceutically acceptable salts thereof. When one or more particular isomers is contemplated, the isomer is indicated, as in *d*-*threo*, *l*-*threo*, etc. The combined *threo* isomers may be indicated simply as "*threo*" and the erythro isomers as "*erythro*". For therapeutic use in treating conditions treatable by methylphenidate drugs, *dl*-*threo* methylphenidate hydrochloride is generally used, while *d*-*threo* methylphenidate hydrochloride is preferred according to the present invention.

[0020] As discussed, the four isomers have exhibited varying levels of therapeutic activity, and have been shown to differ generally in producing unwanted side effects. The present invention provides dosage forms which maximize therapeutic effectiveness and minimize undesirable side effects. In certain preferred embodiments, the dosage forms of the present invention provide administration of the two *threo* forms of methylphenidate. In particularly preferred embodiments, the dosage forms of the present invention provide administration of a single isomer, *d*-*threo*-methylphenidate, albeit in two or more doses.

[0021] The dosage forms of the present invention are intended for oral ingestion by a mammal, particularly a human. The dosage forms of the present invention are particularly suitable for the administration of methylphenidate drugs, in at least two doses. Most preferably, the dosage forms provide two doses of a *d*-*threo* methylphenidate drug such as *d*-*threo* methylphenidate hydrochloride. The second dose can be delayed by from about 2 hours to about 7 hours, preferably from about 3 hours to about 6 hours, and most preferably from about 4 hours to about 5 hours, following ingestion of the dosage form by a mammal. This eliminates the need for a patient, for example a child being treated for ADD, to carry a second dose for ingestion several hours after ingestion of a first dose. The exclusion of the *l* isomers

and the *d*-*erythro* isomer eliminates the concurrent ingestion of forms of methylphenidate principally believed to be associated with adverse side effects and/or reduced effectiveness.

[0022] The temporal separation of the two doses provided according to the present invention can be represented graphically as in Figure 1. Figure 1 is an *in vitro* drug release profile of a dosage form of the present invention. The data were obtained by measuring the rate of dissolution of drug as a function of time. In this embodiment two doses are provided. The release of the first dose preferably occurs substantially immediately; for example, within about 30 minutes following administration. Following a period of little or substantially no drug release, the second dose is released. The two releases can be referred to as "pulses", and such a release profile can be referred to as "pulsatile".

[0023] Figure 2 is a schematic representation of the plasma concentration of drug resulting from a release profile according to Figure 1. The maximum concentration due to the first dose, C_1 , occurs at t_1 , preferably from about 1 hour to about 3 hours after ingestion, most preferably about 2 hours after ingestion. The release of the first dose is followed by a period during which substantially no drug is released, which lasts approximately 2-6 hours, preferably 3-5 hours, post ingestion. The second dose is then released, with the maximum concentration, C_2 , at t_2 , which is preferably about 6 hours post-ingestion. Preferably at least about 80% of the total drug has been released by about 6 hours following administration. In the embodiment represented by Figure 2, the levels of drug released at the two maxima are nearly equal. Preferably, if two approximately equal doses are released, the release of the two doses provides a plasma concentration profile having two maxima, which differ from each other by no more than about 40 percent in magnitude, preferably by no more than about 30 percent, and more preferably by no more than about 25 percent. This is determined by the relationship:

$$|C_1 - C_2| / C_1$$

In such embodiments is most preferred that the maxima differ by no more than 20%. However, embodiments in which the maxima of the two releases differ by more than 40 percent are within the scope of the invention. The appropriate relative amounts of drug in each release can be readily determined by one skilled in the art.

[0024] Dosage forms of the present invention provide controlled release of a methylphenidate drug, including pharmaceutically acceptable salts of methylphenidate, whereby an initial dose for immediate release can be combined with a delayed release of one or more additional doses. Such dosage forms may alternatively be referred to as "pulsatile" dosage forms.

[0025] "Immediate release", as used herein, means release within about a half hour following ingestion, preferably about 15 minutes, and more preferably within about 5 minutes following ingestion. "Delayed release", as used herein, refers to a drug release profile which includes a period during which no more than about 10 percent of the drug in a particular dosage form is released, followed by a period of from about 0.5 hour to about 2.5 hours, preferably about 1.5 hours, more preferably about 1 hour, in which no less than about 70 percent, preferably no less than about 80 percent, and more preferably no less than about 90 percent, of the drug is released. The terms "medication" and "drug" are used interchangeably herein.

[0026] According to the present invention, delayed release dosage forms can be combined with forms which provide immediate release of a drug. Thus, two or more dosage forms can be combined, one dosage form providing a portion of a patient's daily dosage needs of a drug and subsequent dosage forms providing additional portions of a patient's daily dosage needs. For example, a drug can be administered to a patient in two dosage forms simultaneously, one providing, e.g., about 30-50 percent of the patient's daily requirement of the drug and the second providing the remainder of the patient's daily requirement. Alternatively, and preferably, a single dosage form can be administered which includes an immediate dose of some portion of a patient's daily requirement and one or more delayed doses to provide the remaining portion or portions of the patient's daily requirement.

[0027] Dosage forms of the present invention provide an initial dose of a drug such as, for example, a pharmaceutically acceptable salt of *d*-*threo*-methylphenidate (also referred to herein as *d*-MPD), followed by an interval wherein substantially no additional drug is released, followed in turn by release of a second dose. If desired, a second substantially release-free interval may be provided following the second release, followed in turn by a third dose. Thus, dosage forms providing 3 or more doses are contemplated by the present invention. However, dosage forms providing 2 or 3 doses are generally preferred for therapeutic use, with 2 doses being more preferred. For example, the first dose can provide from about 30 percent to about 70 percent of a patient's daily prescribed intake of the drug and the second dose provides from about 70 percent to about 30 percent. If two approximately equal doses are desired, the initial dose preferably provides from about 40 percent to about 60 percent, and the second dose preferably provides from about 60 percent to about 40 percent, of a patient's prescribed daily intake of the drug. If desired, the first dose and the second dose can each provide about 50 percent of a patient's prescribed daily intake of drug. However, as will be apparent to one skilled in the art, the effect of drug metabolism in the body may require adjustment of the relative amounts of each dose, so that, for example, the second dose may have to be adjusted to provide more of the drug

than the first dose, to compensate for any competition between drug release and drug metabolism. This can be observed in Figure 2, which, as discussed above, represents the blood plasma level of a drug, such as a methylphenidate drug, delivered in a dosage form which provides a release profile as illustrated in Figure 1.

[0028] The initial dose of methylphenidate drug in the dosage forms of the present invention can be provided by incorporating the methylphenidate drug into a form which allows for substantially immediate release of the drug once the dosage form is ingested by a patient. Such forms include, for example, powders, coated and uncoated pellets, and coated and uncoated tablets. The dose for immediate release can be administered in a tablet or capsule form which may also include the delayed dose. For example, two or more groups of pellets may be combined within a hard gelatin capsule or compressed into a tablet. Powders can be granulated and can be combined with pellets and excipients and/or other additives, and contained within a capsule or compressed into a tablet. These and other dosage forms will be familiar to those skilled in the art.

[0029] The delayed dose of a methylphenidate drug in the dosage forms of the present invention is provided in part by the use of certain copolymers referred to as "ammonio methacrylate copolymers". Ammonio methacrylate copolymers comprise acrylic and/or methacrylic ester groups together with quaternary ammonium groups. According to the present invention, the copolymers are incorporated into a formulation which is used to coat particles containing a medication.

[0030] The "acrylic and/or methacrylic ester groups" in the copolymers used in the compositions and methods of the present invention are referred to herein collectively as "acrylic groups". The acrylic groups are preferably derived from monomers selected from C₁-C₆ alkyl esters of acrylic acid and C₁-C₆ alkyl esters of methacrylic acid. Preferred are C₁-C₄ alkyl esters of acrylic acid and methacrylic acid. Suitable monomers include, for example, methyl acrylate, ethyl acrylate, methyl methacrylate, and ethyl methacrylate. Ethyl acrylate and methyl methacrylate are preferred, and copolymers containing ethyl acrylate and methyl methacrylate are highly preferred. Also preferably, the copolymers have a molecular weight of about 150,000.

[0031] Quaternary ammonium groups in copolymers useful in forming coatings for use in the dosage forms of the present invention can be derived from monomers comprising quaternary ammonium groups. Preferably, the monomers are alkyl esters of acrylic or methacrylic acid, comprising alkyl groups having from 1 to 6 carbon atoms and a quaternary ammonium group in the alkyl portion. Monomers comprising quaternary ammonium groups can be prepared, for example, by reaction of monomers containing amino groups with alkylating agents such as, for example, alkyl halides, especially methyl chloride. Suitable monomers containing amino groups include 2-(N,N-dibutylamino) ethyl acrylate, 2-(N,N-dibutylamino) ethyl methacrylate, 4-diethylamino-1-methyl-butyl acrylamide, and 4-diethylamino-1-methyl-butyl methacrylamide. Other useful monomers containing amino groups are disclosed in U.S. Patent No. 5,422,121, the disclosure of which is incorporated herein by reference. Particularly preferred as a monomer comprising a quaternary ammonium group is trimethylammonioethyl methacrylate chloride (TAMC1).

[0032] While ammonio methacrylate copolymers such as those described herein have been used for sustained delivery of certain medicaments, i.e., for the relatively constant administration of a drug, it has been surprisingly and unexpectedly found that dosage forms comprising a methylphenidate drug and a coating prepared from one or more ammonio methacrylate copolymers and certain fillers, can provide delayed or pulsatile release of the drug, a very distinct phenomenon. Methylphenidate drugs are amine-containing, rely upon body or membrane loading for efficacy, and are psychotropic. The ability to provide delayed release of a methylphenidate drugs using ammonio methacrylate copolymers is due to a combination of factors, including the composition of the ammonio methacrylate copolymers used, and the amount and composition of filler.

[0033] The ratio of acrylic groups to quaternary ammonium groups in the ammonio methacrylate copolymers influences the properties of the copolymers utilized in forming the coatings of the present invention. For use in the dosage forms and methods of the present invention, the ratio of acrylic groups to quaternary ammonium groups in the copolymers is preferably from about 10:1 to about 50:1, more preferably from about 15:1 to about 45:1. Preferably, in preparing a dosage form according to the present invention, two or more copolymers are used in combination. Also preferably, one of the copolymers comprises acrylic groups and quaternary ammonium groups in a ratio of from about 25:1 to about 45:1, more preferably from about 30:1 to about 40:1, and another of the copolymers comprises acrylic groups and quaternary ammonium groups in a ratio of from about 10:1 to about 25:1, more preferably from about 15:1 to about 20:1. Even more preferably, two ammonio methacrylate copolymers are used: a first copolymer comprising acrylic groups and quaternary ammonium groups in a ratio of from about 30:1 to about 40:1 and the second copolymer comprising acrylic groups and quaternary ammonium groups in a ratio of from about 15:1 to about 20:1. Most preferably, the copolymers are copolymers of methyl methacrylate, ethyl acrylate, and TAMC1, in ratios of 2:1:0.1 for the first copolymer and 2:1:0.2 for the second copolymer.

[0034] When two such ammonio methacrylate copolymers are used to form the coatings, the relative amounts of the two polymers is partly determinative of the delay and release properties of the dosage forms of the present invention. It is preferred that the ratio between the first polymer, most preferably having an acrylic group/quaternary ammonium group ratio of from about 30:1 to about 40:1, and the second polymer, most preferably having an acrylic group/quater-

nary ammonium group ratio of from about 15:1 to about 20:1, be from about 93:7 to about 97:3. More preferably, the ratio of the first polymer to the second polymer is from about 96:4 to about 94:6, and most preferably about 95:5.

[0035] Ammonio methacrylate copolymers used in the coatings of the dosage forms of the present invention can be prepared by methods known to those skilled in the art. Exemplary methods include emulsion polymerization, bulk polymerization and suspension polymerization. A suitable procedure is described in U.S. Patent No. 3,979,349, the disclosure of which is incorporated herein by reference. Suitable ammonio methacrylate copolymers are known *per se*, and can be purchased from commercial providers. For example, suitable ammonio methacrylate polymers are available from Hüls America under the Eudragit® trademarks. The Eudragit® polymers and similar polymers, including methods for preparation, are described in Klaus O. R. Lehman, "Chemistry and Application Properties of Polymethacrylate Coating Systems", *Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms*, 2nd. Ed., pp. 101-174, James Mc Ginity, Ed., Marcel Dekker, Inc., NY (1996), the disclosure of which is incorporated herein by reference.

[0036] The coatings of the present invention also preferably include a filler. The filler is preferably in powder form and is preferably hydrophobic. Exemplary fillers include talc, colloidal silica, fumed silica, gypsum, and glycerine monostearate. Talc is a particularly preferred filler.

[0037] The quantity of filler used in preparing coatings for the dosage forms of the present invention should be sufficient to minimize agglomeration of the particles. Agglomeration is highly undesirable because the agglomerates, rather than discrete particles, will become coated. Agglomerates are susceptible to breaking into discrete particles, which will be partially uncoated, resulting in unwanted variability in release rates. Preferably, the amount of filler is from about 30 percent to about 50 percent by weight, based on the total weight of the dry polymer, commonly referred to as "total solids". More preferably the amount of filler is from about 35 percent to about 45 percent of total solids, and most preferably about 40 percent.

[0038] Coatings used in the dosage forms of the present invention also preferably include a material which improves the processing of the copolymers. Such materials are generally referred to as "plasticizers" and include, for example, citric acid esters, adipates, azelates, benzoates, citrates, stearates, isoebucates, sebacates, propanetriol acetate, polyethylene glycols, diethyl phthalate, dibutyl sebacate, propylene glycol and ethylene glycol. Citric acid esters are preferred, and triethyl citrate is particularly preferred. The amount of plasticizer to be used in the coating is preferably from about 10 percent to about 30 percent, more preferably from about 15 percent to about 25 percent, and most preferably about 20 percent, based on the weight of the dry polymer, i.e., total solids.

[0039] Dosage forms of the present invention preferably comprise particles containing *d*-MPD. In one embodiment, the dosage form comprises two groups of particles. A first group of particles provides the initial dose of *d*-MPD. As stated hereinabove, the initial dose can be in powder, pellet or other particulate form and can be uncoated. If the initial dose is in the form of a powder or sufficiently small particles, it can, if desired, be pressed into a solid form such as a tablet or caplet. In this embodiment, the delayed dose is provided by a second group of particles. The second group of particles is preferably in the form of pellets. The pellets can be of any shape, such as, for example, spheroids or ellipsoids, or may be irregularly shaped.

[0040] Suitable pellets for the initial dose and/or the second dose can be formed by, for example, depositing a layer of drug, and optional excipients, carriers, and other optional materials, onto small, pharmaceutically acceptable particles such as nonpareils. Such a layer can be deposited by methods known to those skilled in the art, such as, for example, spraying, using methods and equipment known to those skilled in the art. For example, a Wurster air suspension coater can be used. Spraying can also be accomplished using a pan coating system, wherein the drug is deposited by successive spraying accompanied by tumbling in a rotating pan. Alternatively, pellets can be formed, for either or both of the initial and delayed dose, by extrusion of the drug with suitable plasticizers and other processing aids as necessary.

[0041] Tablets or caplets, or other solid dose forms, comprising the initial dose and/or delayed dose or doses, can conveniently be administered. A solid dose form can be prepared by methods known to those skilled in the art. For example, the *d*-MPD, filler and other optional components may be compressed into tablets or inserted into capsules. If desired, the drug and other components of the dose form can be granulated, using processing aids, fillers, aqueous or non-aqueous solvents, and binders known to those skilled in the art. Granules can be filled into capsules, if desired. Alternatively, the *d*-MPD can be blended with a solvent and processed by known methods such as ball-milling, calendering, stirring, or roll-milling, then pressed into a desired shape. Suitable solvents useful in forming the particles comprising *d*-MPD, and other components of the dosage forms of the invention, include inert organic and inorganic solvents which do not adversely affect the components of the dosage forms. While water can be used for many drugs, including methylphenidate, useful solvents can be selected from the group consisting of aqueous solvents, alcohols, ketones, esters, ethers, aliphatic hydrocarbons, halogenated solvents, cycloaliphatics, aromatic heterocyclic solvents, and mixtures thereof. Other solvents include acetone, methanol, ethanol, isopropyl alcohol, butyl alcohol, methyl acetate, ethyl acetate, isopropyl acetate, *n*-butyl acetate, methyl isobutyl ketone, methyl propyl ketone, *n*-hexane, *n*-heptane, ethylene glycol monoethyl ether, ethylene glycol monoethyl acetate, methylene dichloride, ethylene dichloride, propylene dichloride, nitroethane, nitropropane, tetrachloroethane, diglyme, and aqueous and non-aqueous mixtures thereof, such as acetone and water, acetone and methanol, acetone and ethyl alcohol, and ethylene dichloride and

methanol.

[0042] Following the formation of suitable particles, those particles to be used to deliver the delayed dose are then coated with a polymer-containing coating as described herein. The amount of coating to be used in forming the dosage forms, particularly the delayed dose, of the present invention, will be determined by the desired delivery properties, including the amount of drug to be delivered, the delay time required, and the size of the particles. Preferably, the coating on the particles providing the delayed dose, including all solid components of the coating such as copolymer, filler, plasticizer and optional additives and processing aids, is from about 10 percent to about 60 percent, more preferably from about 20 percent to about 50 percent, most preferably from about 30 percent to about 40 percent, of the total final weight of the particles. The appropriate amount of coating can advantageously be determined using *in vitro* measurements of drug release rates obtained with selected amounts of coating. The coating can be deposited by any method known to those skilled in the art, such as spray application. Spraying can be carried out by pan coating or by use of a fluid bed, such as the Wurster fluid bed described for use in depositing a drug.

[0043] After deposition of the drug, a sealant can be applied to any and/or all of the particles, prior to application of the polymeric coating. A sealant provides a physical barrier between the drug and the coating, to minimize or prevent interaction between the drug and the coating. Suitable sealants can be prepared from materials such as biologically inert, permeable, pharmaceutically acceptable polymers, such as, for example, hydroxypropylalkylcelluloses, wherein "alkyl" refers to C₁-C₆ hydrocarbon chains. Exemplary materials include hydroxypropyl methylcellulose, hydroxypropylethylcellulose, hydroxypropyl propylcellulose, and hydroxypropylbutylcellulose. Hydroxypropylmethylcellulose is preferred. While other materials are known to those skilled in the art for use as sealants, such as, for example, cellulose acetate methyl carbamate, cellulose acetate diethyl aminoacetate, semipermeable polyurethanes, semipermeable sulfonated polystyrenes, semipermeable cross-linked polymers such as poly(vinylbenzyltrimethyl)ammonium chloride, these are not preferred as they may affect the release rate of certain drugs including d-MPD. A sealant can be prepared by adding the material to water, and agitating for a time and at a rate sufficient to form a solution. The formation of a solution will be indicated, for example, by transparency and the absence of visually observable suspended material. The amount of material added to the water is not critical but is determined by viscosity. A solution which is too viscous will present difficulties in spraying. Generally, the amount of material should not exceed about 20 weight/volume percent, i.e., 20 g sealant material per 100 ml of water. Preferably, the amount of material in the water is from about 5 percent to about 15 weight/ volume percent, and more preferably about 10 weight/volume percent.

[0044] Following deposition of the optional sealant and the coating, the coated particles are cured. "Curing" means that the particles are held at a controlled temperature for a time sufficient to provide stable release rates. Stability in release rate is indicated when further curing does not affect the release rate. In contrast, instability of release rate means that as the cure time is increased, the release rate continues to vary. Curing for a sufficient time ensures that substantially the same release rate is obtained with all particles of a particular size coated with a given amount of a given coating composition. A suitable curing time can be determined by one of skill in the art without undue experimentation, by noting the variability in *in vitro* release times as curing time is varied. As a general guideline, many formulations can be cured in about 24 hours.

[0045] Curing can be accomplished, for example, in a forced air oven. Curing can be carried out at any temperature above room temperature, "room temperature" being defined as from about 18°C to about 25°C. Preferably, curing is carried out at a temperature of from about 30°C to about 50°C, more preferably from about 35°C to about 45°C, and most preferably about 40°C. Curing time can range from several hours to several days. Preferably, the coated particles are cured for at least about 24 hours, more preferably at least about 2 days, even more preferably at least about 3 days, still more preferably at least about 4 days, still even more preferably at least about 5 days, even more preferably at least about 6 days, and most preferably for about 7 days. While no significant adverse effects or advantages have been observed when the particles are cured for longer than about 7 days, it has been found that curing for less than about 24 hours may result in relatively poorer storage stability as compared to particles cured for longer periods of time.

[0046] The amount of methylphenidate drug contained in the first and second groups of particles depends upon the prescribed dosage to be delivered to a patient. The first group of particles can consist substantially entirely of a methylphenidate drug. "Substantially entirely" means that about 95 percent or more of the weight of the first group of particles can consist of a methylphenidate drug. If desired, the first group of particles can also contain pharmaceutically acceptable carriers, excipients, and other components which do not interfere with the substantially immediate release of the medication. "Substantially immediate" release, as used herein, means that at least about 90 percent of the medication is released within about 30 minutes from the time the drug is ingested. The second group of particles can contain from about 2 percent to about 75 percent, preferably from about 4 percent to about 50 percent, medication, based on the total weight of the particles including the coating to be deposited thereon.

[0047] According to the invention, a first and a second group of particles can be administered simultaneously as part of one dosage form. Any dosage form can be used. For example, the two groups of particles can be combined within a capsule. Alternatively, the two groups of particles can be pressed into a solid form such as a tablet. In pressing the particles into a solid form, suitable processing aids known to those skilled in the art can be used. Alternatively, particles

coated to provide a delayed dose of a medication can be dispersed within or blended with, the medication in powder form.

[0048] As discussed, the dosage form can comprise a single group of particles providing both a substantially immediate dose of a methylphenidate drug, and a delayed dose of methylphenidate drug. The particles comprise, in admixture with one or more binders, from about 2% to about 75% by weight of a methylphenidate drug for delayed release, and a coating comprising the pharmaceutically acceptable, substantially neutral copolymers described herein. The particles further comprise, exterior to the coating, an outer layer comprising methylphenidate drug, to provide an initial, substantially immediate, dose. The substantially immediate dose is preferably released within about 30 minutes, more preferably about 15 minutes, and most preferably within about 5 minutes following ingestion. The outer layer can optionally comprise additives such as, for example, binders, excipients, and lubricants known to those skilled in the art.

[0049] The dosage forms provided by the invention can be of any shape suitable for oral administration of a drug, such as spheroidal, cube-shaped, oval, bean shaped, or ellipsoidal. The dosage form may be in the form of granules, which may be irregularly shaped. In any of the embodiments of the present invention, although the size of the particles is generally not critical, a certain particle size or sizes can be preferred depending upon the characteristics of the dosage form. For example, the dosage form can comprise a capsule containing a first and/or second group of particles.

The particles should then be of a size which allows for ease in handling, and which allows for the particles comprising a desired quantity of drug to be readily measured and inserted into the capsule. If the dosage form comprises a single group of particles providing a substantially immediate dose and a delayed dose, the particles are preferably of a size and shape which facilitate oral administration. For example, the particles can be in the form of tablets, caplets, etc.

20 Alternatively, the particles can be contained within a capsule of suitable size and shape for oral administration. If desired, various fillers and/or binders known to those skilled in the art can be included in the particles to provide the desired size and shape.

[0050] It will be recognized by one skilled in the art that the dosage forms of the present invention may include, in either or both of the first dose and any delayed dose, pharmaceutically acceptable carriers, extenders, fillers, processing aids, and excipients known to those skilled in the art.

[0051] The following examples are merely illustrative of the present invention and should not be considered limiting of the scope of the invention in any way. These examples and equivalents thereof will become more apparent to those skilled in the art in light of the present disclosure and the accompanying claims.

30 Example 1: Preparation of layered pellets containing *d*-MPD hydrochloride

[0052] A solution of *d*-MPD hydrochloride was prepared as follows. To 300 grams (g) of deionized water were added 100 g of *d*-MPD hydrochloride, followed by moderate mixing, using a stirring paddle, for 5 minutes. A 10 percent (weight) solution of hydroxypropyl methylcellulose (HPMC E-6 from Dow Chemicals, Midland, MI; 250 g) was added, followed by homogenization for 5 minutes using an emulsifier head (Silverson, Chesham, UK; Model L4R). After addition of another 150 g of deionized water, the solution was sonicated for 15 minutes (Sonicator Model SC-150T; Instruments Corporation, Copiague, NY), at which time the solution was clear.

[0053] A second solution was prepared by combining 300 g of deionized water and 300 g of a 10% (wt) HPMC E-6 solution and mixing for 5 minutes.

[0054] The first solution was sprayed onto 25/30 mesh non-pareil seeds (Ozone Co., Elmwood Park, NJ) in a fluid bed apparatus (GPCG-1, Glatt Air Techniques, Inc., Ramsey, NJ) using a Wurster head. The second solution was then sprayed to form a sealant. For both solutions, the spray rate was 8-9 g/minute. Inlet temperature was 50-55°C and the non-pareil seeds were maintained at 35-40°C. Air volume was 6-7 meters per second (m/s).

45 Example 2: Preparation of Coated Pellets containing *d*-MPD hydrochloride

[0055] A dispersion of 844 g of Eudragit® RS30D (ammoniomethacrylate copolymer from Hüls America, Somerset, NJ; EA/MMA/TAMCI 1:2:0.1), was screened through a 60 mesh screen, then stirred for 15 minutes. A dispersion of 44 g of Eudragit® RL30D (EA/MMA/TAMCI 1:2:0.2) was similarly screened and stirred. The two dispersions were combined and stirred for 15 minutes, forming a combined dispersion. Triethyl citrate (TEC; from Moreflex, Greensboro, NC; 54 g) was added, followed by an additional 15 minutes of stirring. Deionized water (664 g) was added, followed by 15 minutes of stirring. Talc (108 g; from Luzenac, Englewood, CO) was added, followed by further stirring for 15 minutes.

[0056] The resulting combined dispersion was sprayed onto layered pellets prepared according to Example 1, using a fluid bed apparatus as used in Example 1. Spray rate was 9-10 g/minute, inlet temperature 40-45 °C, and air volume 5-6 m/s. The nonpareils were maintained at 30-35 °C during spraying. A total of 960 g of dispersion was sprayed onto the pellets, representing a 30% weight increase due to the applied coating.

EP 1 541 147 A1

Example 3: Evaluation of drug release profile for coated pellets prepared according to

Example 2

5 [0057] Pellets were prepared according to Example 2, varying the ratios of the polymers between 90:10 and 93:7.

Dissolution measurements

10 [0058] Dissolution was carried out in order to determine rate of release of *d*-MPD from the pellets. USP Apparatus I (United States Pharmacopeia Convention, Rockville, MD) was used. The dissolution medium was 900 ml of deionized water (unless otherwise specified) and the temperature was maintained at 37°C. The sample cell size was 1 cm (a flow through cell), and the samples were stirred continuously at 100 rpm. The apparatus was equipped with a diode array spectrophotometer, and absorption at 220 nanometers (nanometers (nm)) was measured to determine the concentration of *d*-MPD. Samples were measured at 60, 120, 180, 240, 360, 480, 600, 720, 840, 900, 960, 1080, 1200, 15 1320 and 1440 minutes.

[0059] Results of the dissolution measurements are presented in Table 1. The results indicate that the amount of drug released is influenced by: amount of coating, ratio of the two polymers, amount of talc, and curing time.

Example 4: Comparative Example

20 [0060] A dispersion of 911.25 g of Eudragit® RS30D was passed through a 60 mesh screen and mixed with a similarly screened dispersion of 101.25 g of Eudragit® RL30D for 15 minutes at moderate speed. Triethyl citrate (61 g) was added, followed by an additional 15 minutes of mixing. After mixing, 991.5 g of deionized water, then 61 g of talc were added with 15 additional minutes of mixing following each addition. The resulting dispersion (1600 g) was sprayed onto 800 g of layered sealed pellets prepared according to Example 1.

[0061] No delay was observed; substantially all of the drug was released within approximately one hour. Result is shown in Table 1 (Trial 1).

Example 5: Comparative Example

30 [0062] A dispersion of 600 g of Eudragit® NE30D was screened through a 60 mesh screen and mixed with a 600 g dispersion of magnesium stearate for 15 minutes at moderate speed. The resulting dispersion (750 g) was sprayed onto 750 g of layered and sealed pellets prepared according to Example 1.

[0063] After a delay of 2 hours, release of the drug was observed. About 85% of the drug was released after 14 total hours.

TABLE 1:

RELEASE TIMES							
	Trial No.	% coat	Ratio	Delay	Talc, %	Cure time	Time for 85% release
40	1	40	90:10	none	20.0	24 hrs	1.0
45	2	30	95:5	4.0	20.0	"	8.0
50	3	30	95:5	4.0	20.0	"	8.0
55	4	30	93:7	1.0	20.0	"	3.0
	5	40	93:7	1.0	20.0	"	4.0
	6	30	93.5:6.5	2.0	20.0	"	5.0
	7	40	"	2.0	20.0	"	5.0
	8	30	94.5:5.5	2.0	20.0	"	8.0
	9	40	"	1.0	20.0	"	5.0
	10	30	94:6	2.0	20.0	"	5.0
	11	40	"	2.0	20.0	"	5.0

TABLE 1: (continued)

RELEASE TIMES							
	Trial No.	% coat	Ratio	Delay	Talc, %	Cure time	Time for 85% release
5	12	30	95:5	2.0	40.0	"	5.0
10	13	40	"	3.0	40.0	"	8.0
15	14	30	96:4	4.0	40.0	"	10.0
20	15	40	"	5.0	40.0	"	10.0
	16	30	"	4.0	40.0	7 days	10.0
	17	20	95:5	2.0	40.0	"	5.0
	18	30	"	3.0	40.0	"	6.0
	19	30	"	3.0	40.0	"	6.0
	20	30	"	2.0	40.0	"	6.0
	21	40	"	3.0	40.0	"	8.0

[0064] Further embodiments of the invention are:

25 1. A dosage form for the oral administration of a methylphenidate drug, comprising two groups of particles, each containing said drug, wherein:

30 a) said first group of particles provides a substantially immediate dose of said drug upon ingestion by a mammal, and
b) said second group of particles comprises coated particles, said coated particles comprising from about 2% to about 75% by weight of said drug in admixture with one or more binders, said coating comprising a pharmaceutically acceptable ammonio methacrylate in a quantity sufficient to provide a dose of said medication delayed by from about 2 hours to about 7 hours following said ingestion.

35 2. The dosage form of embodiment 1 wherein said first group of particles comprises a pharmaceutically acceptable salt of methylphenidate in powder form.

40 3. The dosage form of embodiment 1 wherein said second group of particles comprises coated particles comprising a pharmaceutically acceptable salt of methylphenidate.

45 4. The dosage form of embodiment 2 wherein the amount of said pharmaceutically acceptable salt of methylphenidate in said first group of particles is from about 2% to about 99% by weight, based on the weight of said particles.

50 5. The dosage form of embodiment 4 wherein said pharmaceutically acceptable salt of methylphenidate comprises *dl-threo* methylphenidate hydrochloride.

55 6. The dosage form of embodiment 3 wherein said pharmaceutically acceptable salt of methylphenidate comprises *dl-threo* methylphenidate hydrochloride.

7. The dosage form of embodiment 1 wherein said second group of particles comprises from about 20 % by weight to about 50% by weight of filler, based on the total weight of the copolymer.

8. The dosage form of embodiment 7 wherein said filler is selected from the group consisting of talc, colloidal silica, fumed silica, gypsum, and glycerine monostearate.

9. The dosage form of embodiment 8 wherein said filler is talc.

10. The dosage form of embodiment 9 wherein the amount of talc is from about 35 % to about 45% by weight, based on the total weight of the copolymer.

11. The dosage form of embodiment 10 wherein the amount of talc is from about 38% to about 42% by weight, based on the total weight of the copolymer.

12. The dosage form of embodiment 11 wherein the amount of talc is about 40% by weight, based on the total weight of the copolymer.

13. The dosage form of embodiment 1 wherein the ammonio methacrylate copolymer comprises acrylic groups and quaternary ammonium groups in a ratio of from about 10:1 to about 50:1.

14. The dosage form of embodiment 13 wherein said ratio is from about 15:1 to about 45:1.

15. The dosage form of embodiment 14 wherein said ratio is from about 15:1 to about 20:1.

16. The dosage form of embodiment 15 wherein said ratio is from about 30:1 to about 40:1.

17. The dosage form of embodiment 1 comprising a first ammonio methacrylate copolymer comprising, as polymerized units, acrylic groups and trimethylammonioethyl methacrylate in a ratio of from about 30:1 to about 40:1, and a second ammonio methacrylate copolymer comprising, as polymerized units, acrylic groups and trimethylammonioethyl methacrylate in a ratio of from about 15:1 to about 20:1

5 18. The dosage form of embodiment 17 wherein the ratio of said first copolymer to said second copolymer is from about 90:10 to about 99:1.

19. The dosage form of embodiment 18 wherein the ratio of said first copolymer to said second copolymer is from about 93:7 to about 97:3.

10 20. The dosage form of embodiment 19 wherein the ratio of said first copolymer to said second copolymer is about 95:5.

21. The dosage form of embodiment 1 wherein said delay is from about 3 hours to about 6 hours.

22. The dosage form of embodiment 1 wherein said delay is from about 4 hours to about 5 hours.

15 23. A dosage form for once-daily oral administration of a methylphenidate drug comprising:

a) particles comprising from about 2% by weight to about 99% by weight of said methylphenidate drug, in admixture with one or more binders,

20 b) a coating exterior to said methylphenidate drug, comprising an ammonio methacrylate copolymer in a quantity sufficient to provide a dose of said methylphenidate delayed by from about 2 hours to about 7 hours following administration, and

c) on the exterior surface of said coating, a layer comprising said methylphenidate drug, to provide a substantially immediate dose of said methylphenidate upon administration.

25 24. The dosage form of embodiment 23 wherein said methylphenidate is *dl*-*threo*-methylphenidate hydrochloride.

25. The dosage form of embodiment 23 wherein said methylphenidate is *d*-*threo*-methylphenidate hydrochloride.

26. The dosage form of embodiment 23 wherein said coating comprises a first ammonio methacrylate copolymer comprising, as polymerized units, acrylic groups and trimethylammonioethyl methacrylate in a ratio of from about 30:1 to about 40:1, and a second ammonio methacrylate copolymer comprising, as polymerized units, acrylic groups and trimethylammonioethyl methacrylate in a ratio of from about 15:1 to about 20:1.

30 27. A dosage form for the oral administration of *d*-*threo*-methylphenidate hydrochloride comprising two groups of particles, each containing *d*-*threo*-methylphenidate, wherein:

a) said first group of particles comprises *d*-*threo*-methylphenidate hydrochloride and provides a substantially immediate dose of said *d*-*threo* methylphenidate upon ingestion by a mammal, and

35 b) said second group of particles comprises coated particles, said coated particles comprising from about 2% to about 75% by weight of *d*-*threo*-methylphenidate hydrochloride in admixture with one or more binders, said coating comprising a pharmaceutically acceptable ammonio methacrylate copolymer in an amount sufficient to provide a dose of said *d*-*threo*-methylphenidate delayed by from about 2 hours to about 7 hours following said ingestion.

40 28. A dosage form of a pharmaceutically acceptable salt of *d*-*threo*-methylphenidate providing an *in vitro* release profile comprising two pulses of drug release, wherein said pulses are temporally separated by from about 2 hours to about 7 hours.

45 29. A dosage form of a pharmaceutically acceptable salt of *d*-*threo*-methylphenidate providing an *in vivo* plasma concentration of said *d*-*threo*-methylphenidate comprising two maxima, wherein said maxima are temporally separated by from about 2 hours to about 7 hours, and wherein the magnitude of said maxima differ by no more than about 30 percent.

50 30. A dosage form according to embodiment 23 wherein said ammoniomethacrylate copolymer comprises a first copolymer of methyl methacrylate, ethyl acrylate and TAMCI in a ratio of 2:1:0.1 and a second copolymer of methyl methacrylate, ethyl acrylate, and TAMCI in a ratio of 2:1:0.2.

31. A method for treating disease in a patient in need of treatment comprising administering to the patient a dosage form providing once-daily oral administration of *d*-*threo*-methylphenidate hydrochloride, said dosage form comprising two groups of particles, each containing *d*-*threo*-methylphenidate, wherein:

55 a) said first group of particles comprises from about 2% to about 99% by weight of *d*-*threo*-methylphenidate hydrochloride and provides a substantially immediate dose of said *d*-*threo* methylphenidate upon ingestion by a mammal; and

b) said second group of particles comprises coated particles, said coated particles comprising from about 2% to about 75% by weight of *d*-*threo*-methylphenidate in admixture with one or more binders, and a coating consisting of an ammonio methacrylate copolymer in an amount sufficient to provide a dose of said *d*-*threo*-methylphenidate hydrochloride delayed by from about 4 hours to about 7 hours following said ingestion.

5 32. A dosage form of a pharmaceutically acceptable salt of a methylphenidate providing an *in vitro* release profile comprising two pulses of drug release, wherein said pulses are temporally separated by from about two hours to about seven hours.

10 33. A dosage form of a pharmaceutically acceptable salt of a methylphenidate providing an *in vivo* plasma concentration of said methylphenidate comprising two maxima, wherein said maxima are temporally separated by from about two hours to about seven hours and wherein the magnitude of said maxima differ by no more than about 30%.

15 **Claims**

1. A dosage form of a pharmaceutically acceptable salt of *d*-*threo*-methylphenidate providing an *in vivo* plasma concentration of said *d*-*threo*-methylphenidate comprising two maxima, wherein said maxima are temporally separated by from about 2 hours to about 7 hours, and wherein the magnitude of said maxima differ by no more than about 30 percent.

2. A dosage form of a pharmaceutically acceptable salt of a methylphenidate providing an *in vivo* plasma concentration of said methylphenidate comprising two maxima, wherein said maxima are temporally separated by from about two hours to about seven hours and wherein the magnitude of said maxima differ by no more than about 30%.

25 3. The dosage form of claim 2 wherein the temporal separation is at least about 3 hours.

4. The dosage form of claim 2 wherein the temporal separation is at least about 4 hours.

30 5. A solid dosage form of a pharmaceutically acceptable salt of a methylphenidate providing an *in vivo* plasma concentration of said methylphenidate comprising two maxima, wherein said maxima are temporally separated by from about two hours to about seven hours and wherein the magnitude of said maxima differ by no more than about 30%.

35 6. The solid dosage form of claim 5 wherein said methylphenidate is *d*-*threo*-methylphenidate.

7. A tablet comprising a pharmaceutically acceptable salt of a methylphenidate providing a *in vivo* plasma concentration of said methylphenidate comprising two maxima, wherein said maxima are temporally separated by from about two hours to about seven hours and wherein the magnitude of said maxima differ by no more than about 30%.

40 8. The tablet of claim 7 wherein said methylphenidate is *d*-*threo*-methylphenidate.

9. A capsule comprising a pharmaceutically acceptable salt of a methylphenidate providing a *in vivo* plasma concentration of said methylphenidate comprising two maxima, wherein said maxima are temporally separated by from about two hours to about seven hours and wherein the magnitude of said maxima differ by no more than about 30%.

45 10. The capsule of claim 9 wherein said methylphenidate is *d*-*threo*-methylphenidate.

50

55




FIG. 1




FIG. 2



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 05 07 5103
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)																
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim																	
X	HUBBARD J W ET AL: "ENANTIOSELECTIVE ASPECTS OF THE DISPOSITION OF DL-THREO-METHYLPHENIDATE AFTER THE ADMINISTRATION OF A SUSTAINED-RELEASE FORMULATION TO CHILDREN WITH ATTENTION DEFICIT-HYPERACTIVITY DISORDER" JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 78, no. 11, 1 November 1989 (1989-11-01), pages 944-947, XP000602091 ISSN: 0022-3549 * page 945; figure 1 * -----	1-10	A61K31/4458 A61K9/50																
X	US 4 137 300 A (SHETH ET AL) 30 January 1979 (1979-01-30) * examples 4,5 *	1-10																	
X	WO 97/03673 A (CHIROSCIENCE LTD) 6 February 1997 (1997-02-06) * page 2, line 7 - page 4, line 12 * -----	1-10	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K -/-																
INCOMPLETE SEARCH																			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>																			
3	Place of search The Hague	Date of completion of the search 20 April 2005	Examiner Muller, S																
<table border="1"> <thead> <tr> <th colspan="2">CATEGORY OF CITED DOCUMENTS</th> <th colspan="2"></th> </tr> </thead> <tbody> <tr> <td>X : particularly relevant if taken alone</td> <td>Y : particularly relevant if combined with another document of the same category</td> <td>T : theory or principle underlying the invention</td> <td>E : earlier patent document, but published on, or after the filing date</td> </tr> <tr> <td>A : technological background</td> <td>C : non-written disclosure</td> <td>D : document cited in the application</td> <td>L : document cited for other reasons</td> </tr> <tr> <td>P : intermediate document</td> <td></td> <td>S : member of the same patent family, corresponding document</td> <td></td> </tr> </tbody> </table>				CATEGORY OF CITED DOCUMENTS				X : particularly relevant if taken alone	Y : particularly relevant if combined with another document of the same category	T : theory or principle underlying the invention	E : earlier patent document, but published on, or after the filing date	A : technological background	C : non-written disclosure	D : document cited in the application	L : document cited for other reasons	P : intermediate document		S : member of the same patent family, corresponding document	
CATEGORY OF CITED DOCUMENTS																			
X : particularly relevant if taken alone	Y : particularly relevant if combined with another document of the same category	T : theory or principle underlying the invention	E : earlier patent document, but published on, or after the filing date																
A : technological background	C : non-written disclosure	D : document cited in the application	L : document cited for other reasons																
P : intermediate document		S : member of the same patent family, corresponding document																	



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 05 07 5103

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	PATRICK K S ET AL: "THE ABSORPTION OF SUSTAINED-RELEASE METHYLPHENIDATE FORMULATIONS COMPARED TO AN IMMEDIATE-RELEASE FORMULATION" BIOPHARMACEUTICS AND DRUG DISPOSITION, WILEY, CHICHESTER, US, vol. 10, no. 2, 1989, pages 165-171, XP009023323 ISSN: 0142-2782 * the whole document * ----- A WO 96/41617 A (APR APPLIED PHARMA RESEARCH S.A; CONTE, UBALDO; MAGGI, LAURETTA; REINE) 27 December 1996 (1996-12-27) * page 9 - page 12; example 1 * -----	1-10	
3			



Although claim 31 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the composition.

Claim(s) searched incompletely:
1-10

Reason for the limitation of the search:

Present claims 1-10 relate to a dosage form defined by reference to a desirable characteristic or property, namely providing an in vivo plasma concentration of a pharmaceutically acceptable salt of a methylphenidate comprising two maxima, wherein said maxima are temporally separated by from about two hours to about seven hours and wherein the magnitude of said maxima differ by more than 30%.

The claims cover all dosage forms having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such dosage forms. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible.

Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the dosage form by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the only two specific dosage forms comprising:

- either a) a first group of particles for immediate release of methylphenidate and b) a second group of coated particles for delayed release of methylphenidate
- or a) particles of methylphenidate, b) a coating for delayed release of methylphenidate and c) a layer for immediate release of methylphenidate.

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 05 07 5103

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-04-2005

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 4137300	A	30-01-1979	BE DE DK ES FR JP NL SE ZA	857957 A1 2736794 A1 371277 A 461742 A1 2361915 A1 53026318 A 7709103 A 7709359 A 7705043 A	20-02-1978 23-02-1978 21-02-1978 01-05-1978 17-03-1978 11-03-1978 22-02-1978 21-02-1978 26-07-1978
WO 9703673	A	06-02-1997	AT AU AU CA CZ DE DE DK EP ES ES WO HU JP PT SK US	224715 T 702371 B2 6466196 A 2223643 A1 9800092 A3 69623970 D1 69623970 T2 841928 T3 0841928 A1 2186790 T3 9703673 A1 9802252 A2 11509228 T 841928 T 2998 A3 5874090 A	15-10-2002 18-02-1999 18-02-1997 06-02-1997 17-06-1998 31-10-2002 05-06-2003 27-01-2003 20-05-1998 16-05-2003 06-02-1997 28-01-1999 17-08-1999 31-12-2002 08-07-1998 23-02-1999
WO 9641617	A	27-12-1996	IT AT CA DE DE WO EP ES PT	MI951223 A1 215816 T 2224267 A1 69620606 D1 69620606 T2 9641617 A1 0833618 A1 2174073 T3 833618 T	09-12-1996 15-04-2002 27-12-1996 16-05-2002 24-10-2002 27-12-1996 08-04-1998 01-11-2002 30-09-2002

发明名称：改进了的哌甲酯药物的多剂量输送

5 摘要：本发明提供了哌甲酯药物的用于口服的剂型。该剂型在被摄取后提供一个基本上立刻释放的哌甲酯剂量，然后在预先决定的时间提供一个或以上的其它剂量。通过提供这样一种药物释放特性，所述剂型消除了病人日常携带的需要和额外摄取剂量。本发明提供的剂型和方法对一般每天要求一次或以上剂量的哌甲酯和其药学上可接受盐的
10 给药是有用的。